AgingNMNAGINGNCT06592859
Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People
A study testing NMN in people with Aging and NMN, run by People's Hospital of Quzhou at 1 site in China.
Trial summary
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging… Read more about this study
- Who is it for?
- Ages 39 to 70 yearsHealthy volunteers can take part
- What is being tested?
- NMN
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 240 participants
- Where
- 1 siteChina
- Study dates
- 23 Aug 2023to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 39 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Local residents of Quzhou or living in Quzhou for over ten years.
- age 40-50 and 60-70 years old, no major bad habits.
- Gender unlimited.
- in good health and has not undergone major surgery within half a year.
- Be able to communicate well with researchers and cooperate with the work during the study.
- Written informed consent can be signed voluntarily.
Who cannot join
- Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug abuse or substance abuse.
- Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).
- Obesity (bmi more than 30).
- Pregnant/lactating women.
- Disease history:
- under 60 years old:
Show all 33Show fewer
- any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).
- coronary artery disease/myocardial infarction/clinically significant congestive heart failure.
- stroke/transient ischemic attack.
- deep vein thrombosis/pulmonary embolism.
- serum creatinine \> 1.5 mg/dl (male).
- poor control of hypertension (although treated, there is still significant hypertension (systolic blood pressure \> 160 mmHg, or diastolic blood pressure \>100 mmHg)).
- history of active liver disease or metabolic acidosis.
- chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2.
- severe autoimmunity/inflammation, such as rheumatoid arthritis, lupus, Crohn\'s disease, etc.
- nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease.
- diabetes mellitus (hemoglobin \> 6.5% or fasting blood glucose \> 126 mg/dL or taking diabetes drugs or insulin treatment).
- recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).
- infectious diseases such as HIV, hepatitis, tuberculosis, etc.
- hand or lower limb disability affects normal function and life.
- older than 60 years:
- any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).
- history of active liver disease or metabolic acidosis.
- chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2.
- severe autoimmunity/inflammation, such as lupus, Crohn\'s disease, etc.
- nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease.
- recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).
- infectious diseases such as HIV, hepatitis, tuberculosis, etc.
- hand or lower limb disability affects normal function and life.
- Currently taking the following drugs regularly:
- chemotherapy drugs (such as tamoxifen, adriamycin, mitoxantrone, bleomycin). B) antiplatelet drugs (e.g., clopidogrel/Plavix, dipyridamole/anglionide, ticlopidine/ticlopidine, except aspirin).
- cholinesterase inhibitors for Alzheimer\'s disease (donepezil/alicept).
- The researchers believe that the physical factors of the participants may have an adverse impact on the research process or results.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
People's Hospital of Quzhou
Quzhou, Zhejiang, 324000
Beier Jiang, +86-18367091390, beierjiang@wmu.edu.cn
Feng Zhang, Professor
About this study
Official title: Quzhou Population Cohort Research Project (Aging Related Research: Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People)
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
- Being tested
- NMN, placebo
- Keywords
- Aging, NMN
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NMNDietary supplement
NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.
placeboDietary supplement
Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
| Study group | Role | What they receive |
|---|---|---|
| NMN treated (middle-aged female) | Experimental | NMN Arm participants (middle-aged female) took one capsule (containing 350mg NMN) with breakfast daily for one year. Receives: Dietary Supplement: NMN |
| Placebo (middle-aged male) | Placebo comparator | Placebo arm participants (middle-aged male) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year. Receives: Dietary Supplement: placebo |
| NMN treated (middle-aged male) | Experimental | NMN Arm participants (middle-aged male) took one capsule (containing 350mg NMN) with breakfast daily for one year. Receives: Dietary Supplement: NMN |
| NMN treated (old female) | Experimental | NMN Arm participants (old female) took one capsule (containing 350mg NMN) with breakfast daily for one year. Receives: Dietary Supplement: NMN |
| NMN treated (old male) | Experimental | NMN Arm participants (old male) took one capsule (containing 350mg NMN) with breakfast daily for one year. Receives: Dietary Supplement: NMN |
| Placebo (middle-aged female) | Placebo comparator | Placebo arm participants (middle-aged female) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year. Receives: Dietary Supplement: placebo |
| Placebo (old male) | Placebo comparator | Placebo arm participants (old male) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year. Receives: Dietary Supplement: placebo |
| Placebo (old female) | Placebo comparator | Placebo arm participants (old female) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year. Receives: Dietary Supplement: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comprehensive evaluation of NMN in reducing biological age
Change in biological age from baseline to 12 months, quantified using predefined multi-layer aging clock(s).
Biological age will be assessed using the following measures:
- Transcriptomic age (years)
- DNA methylation age (years)
- Proteomic age (years)
- Metabolomic age (years)
- Phenotypic age (years)
The primary endpoint will be defined as:
Change from baseline to 12 months in a prespecified composite biological age score, derived from the above aging clocks using a predefined integration method (e.g., standardized z-score aggregation or principal component-based integration).
A reduction in biological age is defined as a decrease in the composite biological age score.
Measured: Baseline, 6 months and 12 months
Secondary outcomes (1)
Composite through clinical physical examination data, behavioral indicators and multilevel omics data, to discover new sensitive biomarkers for evaluating aging.
NMN intervention-associated changes will be evaluated across predefined domains:
- Clinical examination parameters, such as:
- Bone mineral density (g/cm²)
- Pulmonary function, including FEV1 (L), FVC (L), and FEV1/FVC (%) Each parameter will be analyzed individually.
- Functional performance measures, such as:
- Grip strength (kg)
- Purdue Pegboard Test completion time (s) Improvement is defined as an increase in grip strength and a decrease in completion time.
- Inflammatory and clinical biomarkers, such as: Circulating inflammatory markers (e.g., IL-6 [pg/mL], CRP [mg/L]) Improvement is defined as a reduction in these markers.
- Multi-omics-derived aging biomarkers, such as:
Gene expression, proteomic, and metabolomic profiles related to metabolism, immunity, and aging. These measures will be summarized using:
Predefined composite aging scoresm, biological ages, or principal component-based or pathway-level summaries, depending on the analysis framework.
Measured: Baseline, 6 months and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start23 Aug 2023
- Primary completion24 May 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- People's Hospital of Quzhou
- Sponsor type
- University, hospital or other
- Collaborators
- Beijing Institute of Genomics, Chinese Academy of Sciences, Institute of Zoology, Chinese Academy of Sciences
- Responsible party
- Principal investigator, Feng Zhang, People's Hospital of Quzhou
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06592859
- Sponsor's protocol ID
- 2023-049
- Other IDs
- MR-33-24-001563
- Acronym
- NMNAGING
- Status last verified
- Mar 2026
- First submitted
- 30 Jul 2024
- Last updated
- 8 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quzhou Population Cohort Research Project (Aging Related Research: Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People)
- ClinicalTrials.gov ID
- NCT06592859
- Acronym / sponsor ID
- NMNAGING / 2023-049
- Keywords
- Aging, NMN
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- People's Hospital of QuzhouUniversity, hospital or other
- Collaborators
- Beijing Institute of Genomics, Chinese Academy of Sciences, Institute of Zoology, Chinese Academy of Sciences
- Study start
- 23 Aug 2023 (actual)
- Primary completion
- 24 May 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| NMN treated (middle-aged female) | Experimental | Dietary Supplement: NMNNMN Arm participants (middle-aged female) took one capsule (containing 350mg NMN) with breakfast daily for one year. |
| Placebo (middle-aged male) | Placebo comparator | Dietary Supplement: placeboPlacebo arm participants (middle-aged male) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year. |
| NMN treated (middle-aged male) | Experimental | Dietary Supplement: NMNNMN Arm participants (middle-aged male) took one capsule (containing 350mg NMN) with breakfast daily for one year. |
| NMN treated (old female) | Experimental | Dietary Supplement: NMNNMN Arm participants (old female) took one capsule (containing 350mg NMN) with breakfast daily for one year. |
| NMN treated (old male) | Experimental | Dietary Supplement: NMNNMN Arm participants (old male) took one capsule (containing 350mg NMN) with breakfast daily for one year. |
| Placebo (middle-aged female) | Placebo comparator | Dietary Supplement: placeboPlacebo arm participants (middle-aged female) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year. |
| Placebo (old male) | Placebo comparator | Dietary Supplement: placeboPlacebo arm participants (old male) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year. |
| Placebo (old female) | Placebo comparator | Dietary Supplement: placeboPlacebo arm participants (old female) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year. |
Who may qualify
- Ages
- 39 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Local residents of Quzhou or living in Quzhou for over ten years.
- age 40-50 and 60-70 years old, no major bad habits.
- Gender unlimited.
- in good health and has not undergone major surgery within half a year.
- Be able to communicate well with researchers and cooperate with the work during the study.
Key exclusion criteria (33 listed)
- Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug abuse or substance abuse.
- Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).
- Obesity (bmi more than 30).
- Pregnant/lactating women.
- Disease history:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NMNNMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year. | Dietary supplement | NMN treated (middle-aged female), NMN treated (middle-aged male), NMN treated (old female), NMN treated (old male) |
| placeboPlacebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year. | Dietary supplement | Placebo (middle-aged female), Placebo (middle-aged male), Placebo (old female), Placebo (old male) |
Primary outcome
Comprehensive evaluation of NMN in reducing biological age
Time frame: Baseline, 6 months and 12 months
Change in biological age from baseline to 12 months, quantified using predefined multi-layer aging clock(s). Biological age will be assessed using the following measures: 1. Transcriptomic age (years) 2. DNA methylation age (years) 3. Proteomic age (years) 4. Metabolomic age (years) 5. Phenotypic age (years) The primary endpoint will be defined as: Change from baseline to 12 months in a prespecified composite biological age score, derived from the above aging clocks using a predefined integration method (e.g., standardized z-score aggregation or principal component-based integration). A reduction in biological age is defined as a decrease in the composite biological age score.
1 secondary outcome
Composite through clinical physical examination data, behavioral indicators and multilevel omics data, to discover new sensitive biomarkers for evaluating aging.
Time frame: Baseline, 6 months and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Individual participant dataSharing planned: No
Related trials for Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NMN in people with Aging and NMN, run by People's Hospital of Quzhou at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 33 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Feng Zhang (+86-15657053100, felix.f.zhang@outlook.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comprehensive evaluation of NMN in reducing biological age (time frame: Baseline, 6 months and 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.